← Eichor
Condition: Endometrial Cancer Stage Iv Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Endometrial Cancer Stage Iv

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06413992Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemothera
NA · 1 location(s) · Dana-Farber Cancer Institute · NCT04997096ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07270666Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Phase 1 · 2 location(s) · M.D. Anderson Cancer Center · NCT03968406Molecular and ctDNA Characterization of High-Risk Endometrial Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT07062016PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer
Phase N/A · 1 location(s) · Radboud University Medical Center · NCT03621904Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdH
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06253494Prehabilitation in Gynaecological Cancer Patients
Phase 3 · 1 location(s) · Charles University, Czech Republic · NCT04789694An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV
NA · 1 location(s) · Roswell Park Cancer Institute · NCT06855706Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · 409 location(s) · National Cancer Institute (NCI) · NCT05256225Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel i
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092373CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05410717A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmaco
Phase 1 · 2 location(s) · Vall d'Hebron Institute of Oncology · NCT07593820Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 483 location(s) · National Cancer Institute (NCI) · NCT05564377IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT05039801Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Phase 3 · 317 location(s) · AstraZeneca · NCT07044336QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06917092A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07612891A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 19 location(s) · NiKang Therapeutics, Inc. · NCT06586957Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
Phase 1 · 5 location(s) · EtiraRx Australia Pty Ltd · NCT06533332
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.